



**Final Appraisal Recommendation**  
Advice No: 0718 – May 2018

**Ranibizumab (Lucentis®) 10 mg/ml solution for injection in vial  
and pre-filled syringe**

**Submission by Novartis Pharmaceuticals UK Ltd**

**Recommendation of AWMSG**

**Ranibizumab (Lucentis®) is recommended as an option for use within NHS Wales for the treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration.**

**This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.**

**Additional note(s):**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3233), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	May 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 3233:  
Ranibizumab (Lucentis®) 10 mg/ml solution for injection in vial and pre-filled syringe May 2018